ReproGo is a bio-tech company renowned for its expertise in developing robust cell and tissue models for drug screening and cell therapy.
With a strong focus on restoring blood flow and addressing diabetic complications, ReproGo offers personalised and allogeneic therapies for acute and chronic wounds. Their advanced solutions target diabetic foot ulcers, non-healing wounds, and conditions related to diabetes and cardiovascular diseases, aiming to accelerate healing and mitigate risks such as poor circulation and infection.
Visit website